HPTN 083 study demonstrates superiority of cabotegravir for the prevention of HIV

(FHI360) The HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news